Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. announces Memorial Sloan Kettering Cancer Center's participation in a Phase 1/2 trial for IMNN-001 combined with bevacizumab in advanced ovarian cancer patients. The trial aims to assess minimal residual disease and progression-free survival, with initial results expected within a year. IMNN-001, a DNA-based IL-12 immunotherapy, shows promise in transforming ovarian cancer treatment.
Reference News
IMUNON, Inc. announces Memorial Sloan Kettering Cancer Center's participation in a Phase 1/2 trial for IMNN-001 combined with bevacizumab in advanced ovarian cancer patients. The trial aims to assess minimal residual disease and progression-free survival, with initial results expected within a year. IMNN-001, a DNA-based IL-12 immunotherapy, shows promise in transforming ovarian cancer treatment.